Personal care company Nu Skin (NYSE:NUS) will be announcing earnings results tomorrow after market close. Here's what to expect.
Nu Skin beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $488.6 million, down 6.5% year on year. It was a weak quarter for the company, with revenue guidance for next quarter missing analysts' expectations.
Is Nu Skin a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting Nu Skin's revenue to decline 10.2% year on year to $432.4 million, improving from the 20.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nu Skin has missed Wall Street's revenue estimates five times over the last two years.
Looking at Nu Skin's peers in the personal care segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Coty (NYSE:COTY) delivered year-on-year revenue growth of 7.5%, meeting analysts' expectations, and USANA reported a revenue decline of 8.3%, in line with consensus estimates. USANA traded up 9.6% following the results.
Read the full analysis of Coty's and USANA's results on StockStory.
Investors in the personal care segment have had steady hands going into earnings, with share prices flat over the last month. Nu Skin is down 2.6% during the same time and is heading into earnings with an average analyst price target of $14.5 (compared to the current share price of $12.2).
